Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENS-401 for prevention or treatment of cisplatin-induced ototoxicity in adults with cancer
2021-002705-10Phase 2Active
- Sponsor
- Sensorion
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of arazasetron besylate in cisplatin-induced ototoxicity (2 arms), sponsored by Sensorion. Primary endpoint: Proportion of more than Grade 1 ototoxic ears. Started Dec 2021; status: active.
02
Drugs
arazasetron besylate
03
Conditions
cisplatin-induced ototoxicity
Beyond the preview
Go deeper on 2021-002705-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002705-10.